Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Doses of Olodaterol in Healthy Volunteers
NCT02171806Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2006
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) and asthma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with clinically significant changes in physical examination at Day 32, Number of patients with clinically significant changes in vital signs and 6 more. Started Jan 2006; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on NCT02171806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171806.